Table 1. Baseline characteristics of the EVITA-HF cohort and the diabetes subgroup.
| Diabetes | No diabetes | p-value | Odds Ratio (95%-confidence interval) | |
|---|---|---|---|---|
| n—(%) | 1489 (36.3) | 2612 (63.7) | ||
| Age—yrs ‡ | 70 (62;76) | 68 (55;76) | <0.001 | |
| Male gender—(%) n | 77.8 (1158/1489) | 75.7 (1977/2612) | 0.13 | 1.12 (0.97–1.31) |
| Ischemic heart disease—% (n/total n) | 63.6 (945/1487) | 47.4 (1236/2606) | <0.001 | 1.93 (1.70–2.20) |
| Dilated CMP—% (n/total n) | 25.3 (376/1487) | 37.5 (976/2606) | <0.001 | 0.57 (0.49–0.65) |
| Myocardial infarction—% (n/total n) | 44.7 (666/1489) | 33.6 (876/2608) | <0.001 | 1.60 (1.40–1.82) |
| Revascularization (PCI and/or CABG)—% (n/total n) | 53.8 (764/1421) | 37.3 (917/2457) | <0.001 | 1.95 (1.71–2.23) |
| PCI—% (n/total n) | 39.1 (556/1421) | 28.6 (703/2457) | <0.001 | 1.60 (1.40–1.84) |
| CABG—% (n/total n) | 26.0 (369/1421) | 15.6 (383/2457) | <0.001 | 1.90 (1.62–2.23) |
| Valve surgery/intervention—% (n/total n) | 5.8 (83/1420) | 6.6 (162/2456) | 0.35 | 0.88 (0.67–1.16) |
| Atrial fibrillation—% (n/total n) | 38.3 (571/1489) | 35.2 (920/2610) | 0.047 | 1.14 (1.00–1.30) |
| Hypertension—% (n/total n) | 79.0 (1176/1489) | 64.9 (1695/2612) | <0.001 | 2.03 (1.75–2.36) |
| Stroke—% (n/total n) | 8.3 (124/1488) | 7.5 (196/2609) | 0.35 | 1.12 (0.89–1.41) |
| Peripheral artery disease—% (n/total n) | 14.9 (221/1488) | 8.0 (208/2607) | <0.001 | 2.01 (1.65–2.46) |
| Chronic kidney disease—% (n/total n) | 40.8 (607/1489) | 26.8 (699/2611) | <0.001 | 1.88 (1.64–2.15) |
| Previously hospitalized for heart failure—% (n/total n) | 68.4 (569/832) | 60.1 (861/1433) | <0.001 | 1.44 (1.20–1.72) |
| Implanted device (ICD, CRT-D, CRT-P, PM)—% (n/total n) | 38.4 (571/1486) | 34.5 (899/2609) | 0.011 | 1.19 (1.04–1.35) |
‡ median (quartiles), yrs years, CMP cardiomyopathy, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, PM pacemaker, ICD implantable cardioverter-defibrillator, CRT cardiac resynchronization therapy.